Summit Therapeutics Shares Are Trading Higher After the Company Announced That It Received Marketing Authorization in China for Ivonescimab in Combination With Chemotherapy.
Summit Therapeutics Shares Are Trading Higher After the Company Announced That It Received Marketing Authorization in China for Ivonescimab in Combination With Chemotherapy.
Summit therapeutics 的股票正在交易中上漲，因為該公司宣佈已經在中國獲得了與化療配合使用Ivonescimab的營銷授權。
Summit Therapeutics Shares Are Trading Higher After the Company Announced That It Received Marketing Authorization in China for Ivonescimab in Combination With Chemotherapy. Also, the Company Announced That It Accepted an Unsolicited Offer From an Institutional Investor to Purchase 22,222,222 Shares of Stock at $9.00 per Share and Will Use the Net Proceeds to Advance Clinical Development of Ivonescimab.
Summit Therapeutics的股票價格在公司宣佈其Ivonescimab聯合化療獲得中國營銷授權後上漲。此外，該公司宣佈接受了一家機構投資者以9美元/股的價格購買22222222股股票的非要約收購，並將使用淨收益推進Ivonescimab的臨床發展。